MXPA03002067A - Formas cristalinas novedosas de un inhibidor del factor xa. - Google Patents

Formas cristalinas novedosas de un inhibidor del factor xa.

Info

Publication number
MXPA03002067A
MXPA03002067A MXPA03002067A MXPA03002067A MXPA03002067A MX PA03002067 A MXPA03002067 A MX PA03002067A MX PA03002067 A MXPA03002067 A MX PA03002067A MX PA03002067 A MXPA03002067 A MX PA03002067A MX PA03002067 A MXPA03002067 A MX PA03002067A
Authority
MX
Mexico
Prior art keywords
inhibitor
factor
crystalline forms
novel crystalline
novel
Prior art date
Application number
MXPA03002067A
Other languages
English (en)
Inventor
Rick G Woodward
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of MXPA03002067A publication Critical patent/MXPA03002067A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Liquid Crystal Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
MXPA03002067A 2000-10-05 2001-10-04 Formas cristalinas novedosas de un inhibidor del factor xa. MXPA03002067A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23831600P 2000-10-05 2000-10-05
GBGB0108903.6A GB0108903D0 (en) 2000-10-05 2001-04-10 Novel crystalline forms of a factor Xa inhibitor
PCT/US2001/031087 WO2002028836A1 (en) 2000-10-05 2001-10-04 Novel crystalline forms of a factor xa inhibitor

Publications (1)

Publication Number Publication Date
MXPA03002067A true MXPA03002067A (es) 2003-06-24

Family

ID=22897372

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03002067A MXPA03002067A (es) 2000-10-05 2001-10-04 Formas cristalinas novedosas de un inhibidor del factor xa.

Country Status (14)

Country Link
US (1) US7034160B2 (es)
EP (1) EP1326838B1 (es)
JP (1) JP4177663B2 (es)
AT (1) ATE396177T1 (es)
AU (2) AU1142502A (es)
CA (1) CA2424565C (es)
CY (1) CY1108224T1 (es)
DK (1) DK1326838T3 (es)
ES (1) ES2304396T3 (es)
GB (1) GB0108903D0 (es)
IL (1) IL155189A (es)
MX (1) MXPA03002067A (es)
PT (1) PT1326838E (es)
WO (1) WO2002028836A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6964784B2 (en) * 2002-03-07 2005-11-15 Optigenex, Inc. Method of preparation and composition of a water soluble extract of the bioactive component of the plant species uncaria for enhancing immune, anti-inflammatory, anti-tumor and dna repair processes of warm blooded animals
EA025572B1 (ru) 2011-03-29 2017-01-30 Санофи Лекарственные формы отамиксабана с улучшенной стабильностью
ES2539236T3 (es) * 2011-03-29 2015-06-29 Sanofi Sal de ácido benzoico de Otamixaban
TWI551289B (zh) * 2011-03-29 2016-10-01 賽諾菲公司 具有改良之安定性之奧米沙班調配物
CN104736178A (zh) 2012-06-04 2015-06-24 药品循环公司 布鲁顿酪氨酸激酶抑制剂的晶形
SG11201700849XA (en) 2014-08-07 2017-03-30 Pharmacyclics Llc Novel formulations of a bruton's tyrosine kinase inhibitor
JP7149076B2 (ja) 2015-03-03 2022-10-06 ファーマサイクリックス エルエルシー ブルトン型チロシンキナーゼ阻害剤の薬学的製剤
MA41827A (fr) * 2015-03-27 2018-01-30 Pharmacyclics Llc Formes solvatées d'un inhibiteur de la tyrosine kinase de bruton

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080767A (en) * 1996-01-02 2000-06-27 Aventis Pharmaceuticals Products Inc. Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides
HU228355B1 (en) * 1996-01-02 2013-03-28 Aventis Pharma Inc Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides

Also Published As

Publication number Publication date
ES2304396T3 (es) 2008-10-16
JP2004521082A (ja) 2004-07-15
DK1326838T3 (da) 2008-09-22
CA2424565A1 (en) 2002-04-11
EP1326838A1 (en) 2003-07-16
GB0108903D0 (en) 2001-05-30
AU2002211425B2 (en) 2006-03-02
ATE396177T1 (de) 2008-06-15
IL155189A (en) 2011-11-30
JP4177663B2 (ja) 2008-11-05
CY1108224T1 (el) 2014-02-12
AU1142502A (en) 2002-04-15
CA2424565C (en) 2011-04-26
PT1326838E (pt) 2008-07-08
WO2002028836A9 (en) 2003-11-20
US20030225144A1 (en) 2003-12-04
WO2002028836A1 (en) 2002-04-11
US7034160B2 (en) 2006-04-25
EP1326838B1 (en) 2008-05-21

Similar Documents

Publication Publication Date Title
TNSN07235A1 (en) Crystalline forms of (r)-8-chloro-1-methyl- 2,3,4,5-tetrahydro-1h-3-benzazepine hydrochloride
YU5503A (sh) Nesteroidni supresori zapaljenja
BG106585A (en) Kinase inhibitors as therapeutic agents
DE60236102D1 (en) 1h-indolderivate als hochselektive cyclooxygenase-2-inhibitoren
HUP0302226A3 (en) Substituted pyrrolopyridinone dervatives useful as phosphodiesterse inhibitors, their intermediates and pharmaceutical compositions containing the compounds
MY134892A (en) Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and their use
TW200510325A (en) 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
HK1071886A1 (en) Novel compounds and compositions as cathepsin inhibitors
CY1108224T1 (el) Καινοτομες κρυσταλλικες μορφες ενος αναστολεα του παραγοντα χα
MXPA03005601A (es) Nuevos compuestos y composiciones como inhibidores de catepsina.
MY133969A (en) Indoloquinazolinones
DE50113345D1 (de) Arginin-mimetika als faktor xa-inhibitoren
MXPA03010766A (es) Nuevos compuestos y composiciones como inhibicores de las catepsinas.
HK1045990A1 (en) Novel derivatives and analogues of galanthamin.
DE60114640D1 (en) Antithrombosemittel
DE60216948D1 (en) 4'-methansulfonylbiphenylderivate als hochselektive cyclooxygenase-2-inhibitoren
MXPA04004090A (es) Compuestos substituidos de 1h-quinolin-2-ona.
MXPA03002493A (es) Proceso eficiente para preparacion de un inhibidor del factor xa.
LT2003075A (en) Inhibitor of monoamine uptake
YU34604A (sh) Oligopeptidi kao inhibitori katepsina s i kompozicije koje ih sadrže
DE60212130D1 (en) Carvedilolpolymorph
PL359727A1 (en) Crystalline pharmaceutical
MXPA03001440A (es) Compuestos de trioxepano novedosos.
MXPA03003466A (es) Derivados de piranosido.
AP2001002179A0 (en) 2-Aminocarbonyl-9h-purine derivatives.

Legal Events

Date Code Title Description
FG Grant or registration